Washington and Wall Street have spent decades debating U.S. dependence on China for chips, consumer electronics and manufacturing. Now, China is poised to disrupt another major industry, one that is ...

(Bloomberg) -- Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor ...

Jan 14 (Reuters) - Investors are eyeing a rebound in the U.S. biotech sector in 2026, as more companies are expected to go public amid a renewed deal-making appetite and a lower interest rate scenario ...

Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and ...

America will celebrate not just one, but two momentous anniversaries this year. Two hundred and fifty years ago, the Founding Fathers declared independence from Great Britain to protect Americans’ ...

The new year has ushered in a flow of biotech-specific funds, including $700 million from Andreessen Horowitz (A16z). The Silicon Valley-based venture capitalist announced $15 billion raised across ...